Anthropic IPO

Anthropic, PBC, the maker of Claude, has filed to go public on the Nasdaq Global Select Market under the proposed symbol ANT. Wall Street research notes on Anthropic will appear on Price Target once analysts start coverage. Everything below is taken from the company’s registration statement (S-1/A, Amendment No. 2, filed with the SEC on November 10, 2026) unless marked otherwise.

Offering terms

Proposed ticker ANT (Nasdaq Global Select Market)
Shares offered 825,000,000 Class A shares: 801,351,354 sold by Anthropic and 23,648,646 by selling stockholders
Estimated price range $70.00 to $78.00 per share
Offering size at the range $57.75 billion to $64.35 billion (825 million shares × $70–$78, before the underwriters’ option)
Underwriters’ option Up to 123,750,000 additional Class A shares from Anthropic, for 30 days
Concurrent private placement $26.0 billion of Class N common stock at the IPO price, bought by AMD, Broadcom, Google, Micron, Microsoft, NVIDIA and TSMC Partners
Estimated net proceeds to Anthropic About $84.6 billion from the IPO and the private placement at the $74 midpoint (about $93.7 billion if the underwriters’ option is exercised in full)
Class A shares outstanding after the offering 7,427,991,791 (plus 5,658,680,800 non-voting Class N shares)
Expected first trading day November 19, 2026, as reported by CNBC citing people familiar with the matter (the date is not stated in the filing)

Financials

US$ millions. 2023–2025 are full years ended December 31; the last two columns are the nine months ended September 30.

2023 2024 2025 9M 2025 9M 2026
Revenue 41 386 4,585 2,545 33,242
Operating loss (551) (2,980) (8,060) (5,224) (1,260)
Net loss (1,531) (8,309) (41,965) (25,107) (104,039)

Most of the net loss comes from non-cash changes in the fair value of convertible notes, derivative liabilities and SAFEs: $94.3 billion in the first nine months of 2026. Cash, cash equivalents and short-term investments were $131.8 billion at September 30, 2026 ($212.7 billion pro forma as adjusted for the offering).

Governance and share classes

  • Public benefit corporation. Anthropic is a Delaware PBC. Its stated public benefit purpose is “the responsible development and maintenance of advanced AI for the long-term benefit of humanity.”
  • Class A (offered in the IPO): one vote per share.
  • Class N: held mainly by strategic business partners. Same economic rights as Class A but no votes; generally converts to Class A when sold to an unaffiliated party.
  • Class T: one share held by the Long-Term Benefit Trust, which elects and removes the Class T directors, a majority of the board. No economic rights.
  • Class F: one share held by a company owned by the seven co-founders, carrying 50.1% of the total voting power on general matters (including the election of non-Class T directors). No economic rights.
  • Class E: issued to employees other than the co-founders. Votes only on certain limited matters; no economic rights.

Underwriters

Goldman Sachs and Morgan Stanley are the representatives. The full syndicate: Goldman Sachs, Morgan Stanley, J.P. Morgan, Citigroup, Barclays, Wells Fargo Securities, BofA Securities, Deutsche Bank Securities, RBC Capital Markets, UBS, BMO Capital Markets, BNP Paribas, Crédit Agricole, Jefferies, Mizuho, MUFG, TD Securities, BTIG, Cantor Fitzgerald, Capital One Securities, Macquarie Capital and SG Americas Securities.

Filing history

  • October 26, 2026: S-1 filed publicly
  • November 2, 2026: S-1/A (Amendment No. 1)
  • November 10, 2026: S-1/A (Amendment No. 2), setting the $70–$78 range

Source: Anthropic, PBC filings on SEC EDGAR. Terms are preliminary and may change before pricing. This page summarises public filings and is not investment advice.

The latest price target updates. All in one place.

Price Target © 2021–2026 CARBA · A carba publication

Privacy Policy

Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.